GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.
P/E ratio for GH Research PLC (GHRS)
P/E ratio as of 2023: -8.48
According to GH Research PLC's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -8.48. At the end of 2022 the company had a P/E ratio of -70.87.
P/E ratio history for GH Research PLC from 2019 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -8.48 |
| 2022 | -70.87 |
| 2021 | -131.76 |
| 2020 | -3021.30 |
| 2019 | -4346.77 |